Arnott, I.D.R.; Satsangi, J.
April 2003
Gut;Apr2003 Supplement 1, Vol. 52, pA13
Academic Journal
Introduction: Up to 75% of patients given infliximab for Crohn's disease (CD) will respond. A number of clinical parameters that may predict response have been proposed but none has been reproduced in an independent cohort. We aimed to identify clinical and laboratory markers of response in patients receiving infliximab at our institution. Methods: Seventy four well characterised CD patients (42 females, median age 34 years (IQR 23-42.5)) were assessed. Full clinical data were collected prospectively and blood was taken for inflammatory markers, ASCA and ANCA. Eleven had ileal disease, 25 colonic disease, 28 ileocolonic disease and 10 had recurrence following ilesotomy. Sixteen had received azathioprine for > 3 months and 5 methotrexate. Single infusion infliximab (5 mg/kg) was given for luminal disease (60 patients) and 3 infusions for fistulating disease (14 patients). Disease activity was assessed by the Harvey-Bradshaw index and a response was defined as a reduction of four or more points or a 50% reduction in draining fistula. Results: Those who smoked greater that 5 cigarettes per day for > 6 months were less likely to respond to infliximab than those who did not (11/21 v 39/47, Χ² = 7.0, p = 0.008, OR 0.22 (CI 0.08 to 0.41)). Patients on azathioprine for longer that three months at infusion were more likely to respond (15/16 v 35/52, Χ² = 4.4, p = 0.036, OR 7.31 (CI 3.34 to 10.31)). There was a trend towards better response rates in those with colonic disease (Χ² = 2.7, p = 0.09) and worse response rates in those with perianal disease (Χ²=3.7, p = 0.056). Age at diagnosis, previous surgery, sex, pre-infusion disease activity, CRP, and ASCA/ANCA status did not influence response rates in our cohort. Conclusion: Smoking has a strong adverse effect on response rates to infliximab. Furthermore, patients established on azathioprine for greater than 3 months had greater response rates. Every effort should be made to...


Related Articles

  • Safety and steroid-sparing experience using infliximab for Crohn’s disease at a pediatric inflammatory bowel disease center. Stephens, Michael C.; Shepanski, Melissa A.; Mamula, Petar; Markowitz, Jonathan E.; Brown, Kurt A.; Baldassano, Robert N. // American Journal of Gastroenterology;Jan2003, Vol. 98 Issue 1, p104 

    : ObjectivesThe published experience using infliximab (Remicade, Centocor, Malvern, PA) for the treatment of pediatric Crohn’s disease is limited but suggests utility in the treatment of refractory disease. Experience using infliximab at a large pediatric center is reviewed.: MethodsA...

  • Immunomodulators and “on demand” therapy with infliximab in Crohn’s disease: clinical experience with 400 infusions. Kinney, Timothy; Rawlins, Matthew; Kozarek, Richard; France, Renée; Patterson, David // American Journal of Gastroenterology;Mar2003, Vol. 98 Issue 3, p608 

    : ObjectivesInfliximab has been proven effective for treatment of active Crohn’s and fistulizing Crohn’s disease. We reviewed our experience with infliximab in patients with Crohn’s disease to determine if its combination with immunomodulators leads to better response and...

  • Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn’s disease Van Assche, Gert; Vanbeckevoort, Dirk; Bielen, Didier; Coremans, Georges; Aerden, Isolde; Noman, Maya; D’Hoore, Andre; Penninckx, Freddy; Marchal, Guy; Cornillie, Freddy; Rutgeerts, Paul // American Journal of Gastroenterology;Feb2003, Vol. 98 Issue 2, p332 

    : ObjectivesAlthough the clinical efficacy of infliximab as measured by closure of fistulas in Crohn’s disease has been demonstrated, its influence on the inflammatory changes in the fistula tracks is less clear. The aim of the present study was to assess the behavior of perianal fistulas...

  • Management of Crohn's disease of the ileoanal pouch with infliximab Colombel, Jean-Frederic; Ricart, Elena; Loftus Jr., Edward V.; Tremaine, William J.; Young-Fadok, Tonia; Dozois, Eric J.; Wolff, Bruce G.; Devine, Richard; Pemberton, John H.; Sandborn, William J. // American Journal of Gastroenterology;Oct2003, Vol. 98 Issue 10, p2239 

    : ObjectivesThe occurrence of Crohn''s disease (CD) in a patient with an ileal-pouch anstomosis (IPAA) often results in severe morbidity and significant chance of reservoir loss. We report our experience of the use of infliximab in these patients.: MethodsMedical records of 26 patients with an...

  • Infliximab/mercaptopurine.  // Reactions Weekly;6/25/2011, Issue 1357, p20 

    The article describes the case of a 19-year-old woman with Crohn's disease who developed melanocytic lesions after starting treatment with mercaptopurine and infliximab.

  • Infliximab.  // Reactions Weekly;10/2/2010, Issue 1321, p21 

    The article describes the case of a man who developed multifocal motor neuropathy with conduction block (MMNCB) following treatment with infliximab for Crohn's disease.

  • Infliximab.  // Reactions Weekly;5/26/2012, Issue 1403, p18 

    The article describes the case of an adult woman who developed paradoxical exacerbation of Crohn's disease (CD) after receiving infliximab.

  • Infliximab.  // Reactions Weekly;03/01/2013, Issue 1441, p21 

    The article presents a case study of a 29-year-old woman who developed acute cytolytic hepatitis while receiving infliximab (Remicade) for vulvar Crohn's disease.

  • Infliximab.  // Reactions Weekly;10/16/2010, Issue 1323, p25 

    The article describes the cases of two women who developed Lewis-Summer syndrome (LSS) while receiving treatment with infliximab for Crohn's disease (CD).


Read the Article


Sign out of this library

Other Topics